Organovo settles patent disputes with BICO; receives $1.5M upfront and ongoing royalties

VivoSim Labs, INC.

BICO will pay Organovo $1.5M upfront plus ongoing low-to-high single-digit % royalties on net sales of licensed products.
All civil actions and IPR proceedings between the parties dismissed and terminated.
BICO receives worldwide non-exclusive license to Organovo's foundational bioprinting patent portfolio.
License covers all BICO brands and is perpetual until last patent expires; customary termination provisions included.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.